Britain and America have finalized a major bilateral deal that will keep no import taxes on UK drug products being sold in the American market.
Agreement Details of the Accord
As part of the deal, the UK has committed to increase funding on medicines through the public health system. This pledge secures that duties on these key products will be held at nothing for a timeframe of three years.
This deal is in response to recent threats to dramatically increase import taxes on branded drug imports, with increases mentioned up to 100%.
"This deal with the United Kingdom reinforces the international landscape for new treatments and brings long-overdue fairness to U.S.–U.K. drug exports," an announcement said.
Trade Importance
Medicines represent one of the Britain's most significant exports to the America, which is by far the largest market for leading UK drugmakers.
Trade data reveal that in the one-year period prior to September, the UK sold medicines totaling billions to the US. This amount accounted for nearly one-fifth of British export trade in that timeframe.
"This deal secures employment, increases capital expenditure and paves the way for the UK to establish itself as a global hub for medical research," a government official remarked.
Specific UK Commitments
The deal involves several specific pledges from the UK:
- Price Threshold Increase: The UK will raise the affordability limit at which it deems new treatments to be too expensive by twenty-five percent.
- Higher Drug Budget: There is a target to double total public funding on medicines from 0.3 percent of Gross Domestic Product to 0.6 percent over the coming ten years.
- Refund Ceiling: The amount manufacturers must refund to the NHS to prevent overspending will be restricted at fifteen percent. Previously, rebates were more than 20%.
Recent Tensions
The pact takes place against a long-running dispute between the drug companies and the UK government over spending levels and regulatory access.
These tensions were exacerbated by assertions that US customers were paying several times more for the identical medicines than consumers in the UK and Europe.
In recent months, several major pharmaceutical investments in the UK have been halted or scrapped, while major funding commitments have been pledged toward US facilities.
One official acknowledged that the NHS must spend more on drugs, noting that its spending on drugs had shrunk as a share of its overall budget over the last ten years.
